Matthew Tindall

Matthew Tindall is the Co-Founder and Chief Executive Officer of Flightpath Biosciences, Inc., a clinical-stage life sciences company focused on developing therapeutics for infectious diseases, particularly Lyme disease. He has been in this role since the company's inception in 2019. Under his leadership, Flightpath has initiated significant clinical trials, including the testing of FP-100, a novel narrow-spectrum antibiotic aimed at treating Lyme disease and other related conditions.124

Background and Experience

Tindall holds an MBA with a focus on Finance and Entrepreneurship and a Bachelor's degree in Human Physiology. His professional journey includes various high-level positions in the healthcare sector:

• Founder & CEO at Flightpath Biosciences (2019 - Present)
• Advisor at Parallel Health (2022 - Present)
• Co-Founder of Kodikaz Therapeutic Solutions, Inc. (2017 - Present)
• CEO at Fabric Genomics (2016 - 2017)
• General Manager at IQVIA (2013 - 2016)
• VP of Marketing at Digitas Health (2010 - 2012)
• Previous roles include business development and sales positions at Genzyme Corporation and Eli Lilly.135

Achievements

Tindall's leadership has been pivotal in advancing Flightpath's mission to address significant unmet medical needs in Lyme disease treatment. The company recently began human clinical testing of FP-100, which is designed to selectively target Borrelia burgdorferi, the bacterium responsible for Lyme disease, while minimizing disruption to the gut microbiome.24 This innovative approach represents a potential breakthrough in antibiotic development and treatment strategies for infectious diseases.

In addition to his work with Flightpath, Tindall has been involved with other health initiatives, serving as an advisor for organizations like Courage Health and contributing to various therapeutic solutions within the biotech space.13